DOSEGUY

Cerebroprotein Hydrolysate

weak data

Also seen as: Cerebrolysin, FPF-1070, CH-I

The Dose Guy’s verdict
Sep 1, 2026
5 sources

Run cerebrolysin if you are going to run a brain peptide course. The generic label “cerebroprotein hydrolysate” covers a family of porcine brain digests, and a lab comparison found that products marketed as equivalent had different compositions and lacked relevant biological activity. A CH-I study in children showed real developmental gains, so the class is not empty, but the formulation you source determines whether you are running the compound the trials tested or something else entirely.

Would I take it?Caution, formulation roulette.

What it is

Cerebroprotein hydrolysate is the class name for injectable peptide preparations made by enzymatically digesting porcine brain tissue. The result is a mix of small neuropeptides and free amino acids that crosses the blood-brain barrier. Cerebrolysin is the original and best-studied product in this class, developed in Austria with decades of clinical use in stroke and dementia. Other products manufactured in China and elsewhere carry the same label and claim equivalence.

The problem is that “equivalent” here is loose. The clinical data behind this class was generated with a specific formulation, and a 2024 lab comparison showed that products carrying the same label differed materially. Assuming another product delivers the same mix is a bet, not a fact.

What the research shows

Most RCTs used the cerebrolysin formulation, but CH-I has its own clinical evidence in pediatric development. What is distinct here is the formulation-variability finding and the broader Cochrane picture:

Peptide preparations marketed as similar to cerebrolysin differed in peptide composition and lacked relevant biological activity in laboratory testing.J Med Life 2024 · laboratory comparison
In a 60-person stroke rehabilitation trial, 30 mL daily for 10 days produced superior NIHSS change at day 10, MW 0.79, and day 30, MW 0.75, versus placebo.2018 · double-blind RCT · n=60
Seven acute ischemic stroke trials found that no trial reported poor functional outcome, defined as death or dependence at end of follow-up. All-cause death across 6 trials and 1,517 participants showed little or no difference, RR 0.90, 95% CI 0.61 to 1.32.Cochrane 2020 · 7 RCTs
In 102 children under age 3, CH-I plus rehabilitation produced greater 90-day improvement than rehabilitation alone in fine motor and adaptive functioning, p<0.05.2025 · prospective controlled · n=102
In moderate to severe traumatic brain injury, a prospective meta-analysis found a small to medium effect at day 90, effect size 0.60, p=0.0146.Neurol Sci 2021 · 2 RCTs · n=185

Realistic protocols

5 to 10 mL intramuscular daily for 10 to 20 day courses, repeated every one to three months. Same injection-site management and refrigeration requirements as cerebrolysin. The critical additional step is sourcing: generic cerebroprotein hydrolysate products are not interchangeable with the reference product, and the lab data backs that up. If you cannot verify formulation equivalence, you are not running the same compound the trials tested. The 30 mL clinical schedule showed efficacy in stroke rehabilitation, but that same dose and duration also carried a nonfatal serious adverse event signal in pooled data, so the lower nootropic range is where elective use belongs.

Standard course5–10 mL/day IM10–20 days, then 1–3 months off. Same shape as the cerebrolysin protocol.
Sourcingverify formulationGeneric labels are not equivalent. The lab comparison matters.
Repeatnext courseReassess between courses. 2–4 per year is the typical rhythm.

Side effects

Side-effect profile tracks cerebrolysin data, since most adverse-event reporting used that formulation:

commonInjection-site pain, headache, dizziness. The usual injectable peptide profile.
monitorNonfatal serious adverse events increased versus placebo in pooled stroke data. The safety signal is real and comes from clinical trials, not anecdote.
monitorAllergic reactions are possible with any porcine-derived biological. Anaphylaxis has been documented with the reference product.
unknownFormulation-specific safety is unmeasured for most generic products. A non-reference product may not share the same safety profile as the one in the trials.

Where to buy

RUO.bio–
$24 / 215mg vial$0.11/mg
✓ verified Sep 12
Read review →
Visit →
Arcane Peptides–
$30 / 215mg vial$0.14/mg
✓ verified Sep 12
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.